GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: March 20, 2003, 03:52:32 ; Search time 63 Seconds
(without alignments)
329.954 Million cell updates/sec

Title: US-09-867-958-1
Perfect score: 849
Sequence: 1 MARQHARTLWYDRPMYVFME.....PPAMDDLDDDSDSADDATSN 156

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	849	100.0	156	20	AAY02591	A human progestero
2	843	99.3	156	22	AAM39556	Human polypeptide
3	772	90.9	543	22	AAM39657	Human polypeptide
4	771	90.8	619	22	AAM82707	Human immune/haema
5	690	81.3	196	22	AAM41342	Human polypeptide
6	347.5	40.9	160	22	AAG63379	Amino acid sequenc
7	347.5	40.9	180	23	ABP41768	Human ovarian anti
8	238	28.0	239	22	AAU30460	Novel human secret
9	126	14.8	69	21	AAB59081	Breast and ovarian
10	126	14.8	134	22	AAO02613	Human polypeptide
11	125	14.7	371	22	ABB64334	Drosophila melanog
12	121	14.3	244	21	AAG09812	Arabidopsis thalia
13	121	14.3	258	21	AAG47700	Arabidopsis thalia
14	121	14.3	262	21	AAG32123	Arabidopsis thalia
15	115	13.5	362	22	AAM93819	Human polypeptide,
16	115	13.5	362	22	AAM38909	Human polypeptide
17	115	13.5	362	22	AAB94033	Human protein sequ
18	115	13.5	371	21	AAB56812	Human prostate can
19	115	13.5	371	22	AAM40695	Human polypeptide
20	115	13.5	371	22	AAM40696	Human polypeptide
21	91.5	10.8	704	9	AAP80087	Sequence of 85 kd
22	91.5	10.8	704	23	AAU71813	Trypanosoma antige
23	89.5	10.5	327	12	AAR14026	Human brain tissue
24	89.5	10.5	487	18	AAW26510	Amyloid precursor
25	89.5	10.5	487	18	AAW26394	Amyloid precursor
26	89.5	10.5	487	19	AAW44745	APP-REP 751 protei
27	89.5	10.5	487	19	AAW42979	Amyloid precursor
28	89.5	10.5	492	14	AAR45229	APP-REP 751 amyloi
29	89.5	10.5	492	18	AAW26509	Amyloid precursor
30	89.5	10.5	492	18	AAW26393	Amyloid precursor
31	89.5	10.5	492	19	AAW44744	APP-REP 751 pre
32	89.5	10.5	492	19	AAW42978	Amyloid precur
33	89.5	10.5	596	15	AAR65797	Beta-amyloid precu
34	89.5	10.5	651	15	AAR65796	Beta-amyloid precu
35	89.5	10.5	670	15	AAR65795	APP751 beta-amyloi
36	89.5	10.5	695	9	AAP81692	Sequence of human
37	89.5	10.5	695	11	AAR05166	Sequence of amyloi
38	89.5	10.5	695	12	AAR14046	Amyloid precursor
39	89.5	10.5	695	13	AAR26338	APP695. Homo sapi
40	89.5	10.5	695	18	AAW19487	APP695 mutant A-be
41	89.5	10.5	695	18	AAW19501	APP695 mutant A-be
42	89.5	10.5	695	18	AAW19504	APP695 mutant A-be
43	89.5	10.5	695	18	AAW19498	APP695 mutant A-be
44	89.5	10.5	695	18	AAW19484	APP695 mutant A-be
45	89.5	10.5	695	18	AAW19495	APP695 mutant A-be

ALIGNMENTS

RESULT 1
AAY02591
ID AAY02591 standard; Protein; 156 AA.
XX
AC AAY02591;
XX
DT 19-JUL-1999 (first entry)
XX
DE A human progesterone receptor complex p23-like protein.
XX
KW Human progesterone receptor complex p23-like protein; PR23P;
KW neurological disorder; antagonist; reproductive disorder;
KW immunological disorder; neoplastic disorder.
XX
OS Homo sapiens.
XX
PN WO9919483-A1.
XX
PD 22-APR-1999.
XX
PF 09-OCT-1998; 98WO-US21402.
XX
PR 09-OCT-1997; 97US-0948197.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Corley NC, Shah P, Yue H;
XX
DR WPI; 1999-302530/25.
DR N-PSDB; AAX36136.
XX
PT Human progesterone receptor complex p23-like protein
XX

PS Claim 1; Fig 1A-B; 67pp; English.
XX
CC The present sequence represents a human progesterone receptor complex
CC p23-like protein (PR23P). PR23P is used to treat neurological
CC disorders. Antagonists of PR23P are useful for treating reproductive,
CC immunological or neoplastic disorders. Probes and primers based on the
CC PR23P polynucleotides can be used for diagnosis, detection and screening
CC of homologues, and amplification of PR23P genes. Antisense PR23P
CC polynucleotides can be used to decrease or inhibit expression of PR23P.
XX
SQ Sequence 156 AA;

Query Match 100.0%; Score 849; DB 20; Length 156;
Best Local Similarity 100.0%; Pred. No. 1e-82;
Matches 156; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MARQHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MARQHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60

Qy     61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120

Qy    121 VEHYAELLKKVSTKRPPPAMDDLDDDSDSADDATSN 156
          ||||||||||||||||||||||||||||||||||||
Db    121 VEHYAELLKKVSTKRPPPAMDDLDDDSDSADDATSN 156
```

RESULT 2
AAM39556
ID AAM39556 standard; Protein; 156 AA.
XX
AC AAM39556;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2701.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58712.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2701; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the prin
CC specification.
XX
SQ Sequence 156 AA;

Query Match 99.3%; Score 843; DB 22; Length 156;
Best Local Similarity 99.4%; Pred. No. 4.5e-82;
Matches 155; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy      1 MARQHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60
          ||||||||||||||  ||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MARQHARTLWYDRPRYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60

Qy     61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120

Qy    121 VEHYAELLKKVSTKRPPPAMDDLDDDSDSADDATSN 156
          ||||||||||||||||||||||||||||||||||||
Db    121 VEHYAELLKKVSTKRPPPAMDDLDDDSDSADDATSN 156
```

RESULT 3
AAM39657
ID AAM39657 standard; Protein; 543 AA.
XX
AC AAM39657;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2802.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.

XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58813.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2802; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 543 AA;

Query Match 90.9%; Score 772; DB 22; Length 543;
Best Local Similarity 97.9%; Pred. No. 8.7e-74;
Matches 141; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy      1 MARQHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60
          ||| |||||||||| ||||||||||||||||||||||||||||||||||||||||||||:
Db      1 MARLHARTLWYDRPRYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKL 60

Qy     61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120

Qy    121 VEHYAELLKKVSTKRPPPAMDDLD 144
          |||||||||||||||||||||||
Db    121 VEHYAELLKKVSTKRPPPAMDDLD 144
```

RESULT 4
AAM82707
ID AAM82707 standard; Protein; 619 AA.
XX
AC AAM82707;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:10300.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.

PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK55488.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Claim 11; SEQ ID NO 10300; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM821f
CC represent sequences used in the exemplification of the present inventi
XX
SQ Sequence 619 AA;

Query Match 90.8%; Score 771; DB 22; Length 619;
Best Local Similarity 97.9%; Pred. No. 1.3e-73;
Matches 141; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1 MARQHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60
           ||| |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db      61 MARXHARTLWYDRPRYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKX 120

Qy      61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 180

Qy     121 VEHYAELLKKVSTKRPPPAMDDLD 144
           ||||||||||||||||||||||||
Db     181 VEHYAELLKKVSTKRPPPAMDDLD 204
```

RESULT 5
AAM41342
ID AAM41342 standard; Protein; 196 AA.
XX
AC AAM41342;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 6273.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.

```
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   N-PSDB; AAI60498.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Example 2; SEQ ID NO 6273; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence   196 AA;

  Query Match             81.3%;  Score 690;  DB 22;  Length 196;
  Best Local Similarity   98.4%;  Pred. No. 1.3e-65;
  Matches  125;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 MARQHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 60
           |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db      60 MARQHARTLWYDRPRYVFMEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKV 119

Qy      61 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     120 NSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAH 179

Qy     121 VEHYAEL 127
           |||||||:
Db     180 VEHYAEV 186


RESULT 6
AAG63379
ID   AAG63379 standard; Protein; 160 AA.
XX
AC   AAG63379;
XX
DT   15-OCT-2001  (first entry)
XX
DE   Amino acid sequence of a human prostaglandin E1 (PGE1) synthase.
XX
KW   Human; prostaglandin E1 synthase; PGE1 synthase; arachidonic acid;
KW   inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200157225-A1.
XX
PD   09-AUG-2001.
XX
PF   25-AUG-2000; 2000WO-JP05758.
XX
PR   03-FEB-2000; 2000JP-0032704.
XX
PA   (CHUS ) CHUGAI SEIYAKU KK.
PA   (KUDO/) KUDO I.
XX
PI   Kudo I,  Murakami M,  Ohishi S;
XX
DR   WPI; 2001-483439/52.
DR   N-PSDB; AAH43100.
XX
PT   PGES-1 protein and encoded gene with PGE2 synthase activity, useful in
PT   screening efficient PGE2 synthase inhibitors as antiinflammatory agents
PT   -
XX
PS   Claim 1; Fig 5; 54pp; Japanese.
XX
CC   The present sequence represents a human prostaglandin E1 (PGE1) synthase.
CC   The protein synthesizes PGE2 from arachidonic acid in consort with COX.
CC   The PGE2 synthase protein and gene are useful in screening for efficient
CC   PGE2 synthase inhibitors. These inhibitors are useful as
CC   anti-inflammatory agents.
XX
SQ   Sequence   160 AA;

  Query Match             40.9%;  Score 347.5;  DB 22;  Length 160;
  Best Local Similarity   43.4%;  Pred. No. 3.9e-29;
  Matches   66;  Conservative   30;  Mismatches   53;  Indels    3;  Gaps    2;

Qy       4 QHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSC-KNADGVELYNEIEFYAKVNS 62
           | |   |||| |||:||||||| ||:|  |  :: |||   :|  :  |||: :  ::
Db       2 QPASAKWYDRRDYVFIEFCVEDSKDVNVNFEKSKLTFSCLGGSDNFKHLNEIDLFHCIDP 61

Qy      63 KDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAHVE 122
            ||: ||: ||| | :|| :   :|||||||  |  ||||||:||:||| | : :::: :
Db      62 NDSKHKRTDRSILCCLRKGESGQSWPRLTKERAKLNWLSVDFNNWKDWEDDSDEDMSNFD 121

Qy     123 HYAELLKKVSTKRPP--PAMDDLDDDSDSADD 152
           ::|::  :       | :|  ||||  :||
Db     122 RFSEMMNNMGGDEDVDLPEVDGADDDSQDSDD 153


RESULT 7
ABP41768
ID   ABP41768 standard; Protein; 180 AA.
XX
AC   ABP41768;
XX
DT   22-AUG-2002  (first entry)
XX
DE   Human ovarian antigen HOPKT59, SEQ ID NO:2900.
XX
KW   Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW   ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW   infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW   PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW   inflammatory condition; immune disorder; blood disorder;
KW   cardiovascular disorder; respiratory disorder; neurological disorder;
KW   gastrointestinal disorder; urinary system disorder; drug screening;
KW   gene therapy; chromosome mapping; forensic analysis;
KW   antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW   antiinflammatory; gynaecological; reproductive.
XX
OS   Homo sapiens.
XX
PN   WO200200677-A1.
XX
PD   03-JAN-2002.
XX
PF   07-JUN-2001; 2001WO-US18569.
XX
PR   07-JUN-2000; 2000US-209467P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
```

PI Birse CE, Rosen CA;
XX
DR WPI; 2002-147878/19.
DR N-PSDB; ABQ54845.
XX
PT Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT useful in the prevention, treatment and diagnosis of cancer (e.g.
PT ovarian cancer), immune disorders, cardiovascular disorders and
PT neurological diseases -
XX
PS Claim 11; SEQ ID No 2900; 2922pp; English.
XX
CC The invention relates to 2175 novel human ovarian antigens (ABP41054-
CC ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
CC encompasses polypeptides 90% identical and polynucleotides 95% identical
CC to the sequences of the invention. The invention additionally relates to
CC recombinant vectors and host cells comprising human ovarian antigen
CC polynucleotides, antibodies against human ovarian antigens, and the use
CC of ovarian antigen polynucleotides and polypeptides in diagnosing,
CC treating, prognosing or preventing various ovary and/or breast-related
CC disorders. Such conditions include ovarian cancer and breast cancer, and
CC metastatic tumours of ovarian or breast origin, reproductive system
CC disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
CC vaginitis), immune disorders (e.g., congenital and acquired
CC immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
CC blood-related disorders (e.g., anaemia), cardiovascular disorders,
CC respiratory disorders, neurological disorders, gastrointestinal disorders
CC and urinary system disorders. Ovarian antigen polypeptides and
CC polynucleotides may also be used in screening for compounds which
CC modulate ovarian antigen expression or activity. The polynucleotides may
CC further be used for gene therapy, chromosome mapping, in the
CC identification of individuals and in forensic analysis, and the
CC polypeptides may be used as food additives or to prepare antibodies
CC useful in disease diagnosis, drug targeting and phenotyping. The present
CC sequence represents a human ovarian antigen of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 180 AA;

Query Match 40.9%; Score 347.5; DB 23; Length 180;
Best Local Similarity 43.4%; Pred. No. 4.5e-29;
Matches 66; Conservative 30; Mismatches 53; Indels 3; Gaps 2;

```
Qy       4 QHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSC-KNADGVELYNEIEFYAKVNS 62
           | |   ||||  |||:||||||| ||:|  |  :: |||   :|  :  |||: :  ::
Db      22 QPASAKWYDRRDYVFIEFCVEDSKDVNVNFEKSKLTFSCLGGSDNFKHLNEIDLFHCIDP 81

Qy      63 KDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAHVE 122
            ||: ||: ||| | :|| :   :|||||||  |  ||||||:||:||| | : :::: :
Db      82 NDSKHKRTDRSILCCLRKGESGQSWPRLTKERAKLNWLSVDFNNWKDWEDDSDEDMSNFD 141

Qy     123 HYAELLKKVSTKRPP--PAMDDLDDDSDSADD 152
           ::|::  :        | :|  ||||  :||
Db     142 RFSEMMNNMGGDEDVDLPEVDGADDDSQDSDD 173
```

RESULT 8
AAU30460
ID AAU30460 standard; Protein; 239 AA.
XX
AC AAU30460;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #951.
XX
KW Human; vaccination; gene therapy; nutritional supplement;
KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS Homo sapiens.
XX
PN WO200179449-A2.
XX
PD 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-US08656.
XX
PR 18-APR-2000; 2000US-0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genet-
PT vaccination, testing and therapy -
XX
PS Claim 20; Page 296; 765pp; English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 239 AA;

Query Match 28.0%; Score 238; DB 22; Length 239;
Best Local Similarity 36.8%; Pred. No. 3.3e-17;
Matches 60; Conservative 30; Mismatches 55; Indels 18; Gaps

```
Qy       4 QHARTLWYDRPMYVF-MEFC-VEDSTDVHVLIEDHRIV-FSC----KNADGVELYNEIEF 56
           | |   ||||  ||   ||  :   ||:|  |  :   |||      |  |:   |||:
Db      74 QPASAKWYDRRDYVLKWEFVFLNTLRDVNVNFEKSKTYNFSCLGGSDNFXGI--LNEIDL 131

Qy      57 YAKVNSKDSQDKRSSRSITCFVRK---WKEKVAWPR-LTKEDIKP-VWLSVDFDNWRDWE 111
           :  ::  ||: ||: ||| | :||   |    :||: |||| |  :|:||||:||:|||
Db     132 FHCIDPNDSKHKRTDRSILCCLRKRRIWAS--SWPKGLTKERGKGLIWVSVDFNNWKDWE 189

Qy     112 GDEEMELAHVEHYAELLKKVSTKR--PPPAMDDLDDDSDSADD 152
           | : :::: : ::|::  :        | :|  ||||  :||
Db     190 DDSDEDMSNFDRFSEMMNNMGGDEVVDYPEVDGADDDSQDSDD 232
```

RESULT 9
AAB59081
ID AAB59081 standard; Protein; 69 AA.
XX
AC AAB59081;
XX
DT 27-MAR-2001 (first entry)
XX
DE Breast and ovarian cancer associated antigen protein sequence SEQ ID 789.
XX
KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;
KW nootropic; neurpprotective; antiviral; antiallergic; hepatotropic;

KW antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant;
KW antibacterial; antifungal; antiparasitic; cardiant; immune disorder;
KW Addison's disease; allergy; autoimmune haemolytic anaemia;
KW autoimmune thyroiditis; diabetes mellitus; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;
KW cardiovascular disorder; wound healing; neurological disease.
XX
OS Homo sapiens.
XX
PN WO200055173-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US05881.
XX
PR 12-MAR-1999; 99US-0124270.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2000-611515/58.
DR N-PSDB; AAF21984.
XX
PT New human breast and ovarian cancer associated gene sequences and the
PT polypeptides encoded by these genes, useful in the prevention,
PT treatment and diagnosis of cancer, immune disorders, cardiovascular
PT disorders and neurological diseases -
XX
PS Claim 11; Page 1251-1252; 1299pp; English.
XX
CC Sequences AAF21614 - AAF22031 represent DNA sequences encoding human
CC proteins AAB58711 - AAB59128. The DNA and protein sequences are
CC associated with breast and ovarian cancer. Included in the invention are
CC sequences AAF22032 - AAF22040 and AAB59129 which are used in the
CC isolation and characterisation of the DNA and protein sequences of the
CC invention. The breast and ovarian cancer associated DNA, protein, agonist
CC or antagonist sequences exhibit cytostatic; immunosuppressive;
CC nootropic; neuroprotective; antiviral; antiallergic; hepatotropic;
CC antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant;
CC antibacterial; antifungal; antiparasitic and cardiant activity. The
CC polynucleotide and protein sequences are used in the diagnosis of cancer,
CC particularly breast and ovarian cancer. The nucleic acid sequences,
CC proteins, agonists and agonists may also be used in the diagnosis,
CC prevention and treatment of immune disorders e.g. Addison's disease,
CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC arthritis and ulcerative colitis; cardiovascular disorders such as
CC myocardial ischaemias; wound healing; neurological diseases such as
CC cerebral anoxia and epilepsy; and infectious diseases.
XX
SQ Sequence 69 AA;

Query Match 14.8%; Score 126; DB 21; Length 69;
Best Local Similarity 41.9%; Pred. No. 6e-06;
Matches 26; Conservative 10; Mismatches 26; Indels 0; Gaps 0;

```
Qy      46 DGVELYNEIEFYAKVNSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFD 105
           |  :  | |  :  ::   |: ||: ||| | :|| :   :|  ||||  |  ||||||:
Db       3 DNFKHLNGIXLFHCIDPNGSKHKRTDRSILCCLRKGESGQSWQGLTKERAKLNWLSVDFN 62

Qy     106 NW 107
           ||
Db      63 NW 64
```

RESULT 10
AAO02613
ID AAO02613 standard; Protein; 134 AA.
XX
AC AAO02613;
XX
DT 06-NOV-2001 (first entry)

XX
DE Human polypeptide SEQ ID NO 16505.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.
XX
OS Homo sapiens.
XX
PN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04927.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-514838/56.
DR N-PSDB; AAI82544.
XX
PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -
XX
PS Claim 20; SEQ ID NO 16505; 1399pp + Sequence Listing; English.
XX
CC The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AA000010-AA013910) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 134 AA;

Query Match 14.8%; Score 126; DB 22; Length 134;
Best Local Similarity 24.8%; Pred. No. 1.4e-05;
Matches 31; Conservative 31; Mismatches 49; Indels 14; Gaps 3;

```
Qy      19 MEFCVEDSTDVHVLIEDHRIVFSCKNADGVELYNEIEFYAKVNSKDSQDKRSSRSITCFV 78
           :  ||  ::  |     |:           |:|     :: :| ::| :|::| | | :
Db       8 LNLCVTTASLKHFFSIAHKF----------HLHNGSHLQSQ-HSCEAQLRRTARFIICCL 56

Qy      79 RKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAHVEHYAELLKKVSTKRPPP 138
              :   :|| || |    ||:| |:||:||| | :  ::: :  :|::  :   |
Db      57 PYGESGQSWPTLTLERANLNWLTVYFNNWKDWEYDSDQYMSNFDRSSEMMNIIVWXR--- 113

Qy     139 AMDDL 143
           ::|:|
Db     114 SIDNL 118
```

RESULT 11
ABB64334
ID ABB64334 standard; Protein; 371 AA.
XX
AC ABB64334;
XX
DT 26-MAR-2002 (first entry)

```
XX
DE   Drosophila melanogaster polypeptide SEQ ID NO 19794.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   N-PSDB; ABL08437.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Disclosure; SEQ ID NO 19794; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   371 AA;

  Query Match             14.7%;  Score 125;  DB 22;  Length 371;
  Best Local Similarity   36.2%;  Pred. No. 6.7e-05;
  Matches   34;  Conservative   13;  Mismatches   37;  Indels   10;  Gaps    4;

Qy      45 ADGVELYN-EIEFYAKVNSKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVD 103
           | ||  |  |: ||| :: :::    |   |   :||  |   ||||     || || :|
Db      47 ARGVNAYKFELHFYALIDDENATFVVSDNKIELQIRK-LEPEWWPRLVATPQKPHWLKID 105

Qy     104 FDNWRDWEGDEEME-------LAHVEHYAELLKK 130
           || ||  | | |:|         : : ||:| |:
Db     106 FDRWRT-EDDVEVEEKPRDVRQDYEKEYADLQKR 138


RESULT 12
AAG09812
ID   AAG09812 standard; Protein; 244 AA.
XX
AC   AAG09812;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID NO: 7889.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
XX
OS   Arabidopsis thaliana.
XX
```

```
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-0301439.
XX
PR   25-FEB-1999;   99US-0121825.
PR   05-MAR-1999;   99US-0123180.
PR   09-MAR-1999;   99US-0123548.
PR   23-MAR-1999;   99US-0125788.
PR   25-MAR-1999;   99US-0126264.
PR   29-MAR-1999;   99US-0126785.
PR   01-APR-1999;   99US-0127462.
PR   06-APR-1999;   99US-0128234.
PR   08-APR-1999;   99US-0128714.
PR   16-APR-1999;   99US-0129845.
PR   19-APR-1999;   99US-0130077.
PR   21-APR-1999;   99US-0130449.
PR   23-APR-1999;   99US-0130510.
PR   23-APR-1999;   99US-0130891.
PR   28-APR-1999;   99US-0131449.
PR   30-APR-1999;   99US-0132048.
PR   30-APR-1999;   99US-0132407.
PR   04-MAY-1999;   99US-0132484.
PR   05-MAY-1999;   99US-0132485.
PR   06-MAY-1999;   99US-0132486.
PR   06-MAY-1999;   99US-0132487.
PR   07-MAY-1999;   99US-0132863.
PR   11-MAY-1999;   99US-0134256.
PR   14-MAY-1999;   99US-0134218.
PR   14-MAY-1999;   99US-0134219.
PR   14-MAY-1999;   99US-0134221.
PR   14-MAY-1999;   99US-0134370.
PR   18-MAY-1999;   99US-0134768.
PR   19-MAY-1999;   99US-0134941.
PR   20-MAY-1999;   99US-0135124.
PR   21-MAY-1999;   99US-0135353.
PR   24-MAY-1999;   99US-0135629.
PR   25-MAY-1999;   99US-0136021.
PR   27-MAY-1999;   99US-0136392.
PR   28-MAY-1999;   99US-0136782.
PR   01-JUN-1999;   99US-0137222.
PR   03-JUN-1999;   99US-0137528.
PR   04-JUN-1999;   99US-0137502.
PR   07-JUN-1999;   99US-0137724.
PR   08-JUN-1999;   99US-0138094.
PR   10-JUN-1999;   99US-0138540.
PR   10-JUN-1999;   99US-0138847.
PR   14-JUN-1999;   99US-0139119.
PR   16-JUN-1999;   99US-0139452.
PR   16-JUN-1999;   99US-0139453.
PR   17-JUN-1999;   99US-0139492.
PR   18-JUN-1999;   99US-0139454.
PR   18-JUN-1999;   99US-0139455.
PR   18-JUN-1999;   99US-0139456.
PR   18-JUN-1999;   99US-0139457.
PR   18-JUN-1999;   99US-0139458.
PR   18-JUN-1999;   99US-0139459.
PR   18-JUN-1999;   99US-0139460.
PR   18-JUN-1999;   99US-0139461.
PR   18-JUN-1999;   99US-0139462.
PR   18-JUN-1999;   99US-0139463.
PR   18-JUN-1999;   99US-0139750.
PR   18-JUN-1999;   99US-0139763.
PR   21-JUN-1999;   99US-0139817.
PR   22-JUN-1999;   99US-0139899.
PR   23-JUN-1999;   99US-0140353.
PR   23-JUN-1999;   99US-0140354.
PR   24-JUN-1999;   99US-0140695.
PR   28-JUN-1999;   99US-0140823.
PR   29-JUN-1999;   99US-0140991.
PR   30-JUN-1999;   99US-0141287.
PR   01-JUL-1999;   99US-0141842.
```

PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 14.3%; Score 121; DB 21; Length 244;
Best Local Similarity 27.6%; Pred. No. 0.0001;
Matches 35; Conservative 25; Mismatches 57; Indels 10; Gaps 5;

```
Qy       4 QHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIV-FSCKNADGVELYN-EIEFYAKVN 61
           :|    | :    :|:   : |: |  | ::   :  || |      :|  ::| · |||
Db       3 RHPEVKWAETTEKIFLTVVLADTKDTKVNLDPEGVFDFSAKVGPENHVYELKLELADKVN 62

Qy      62 SKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDE------E 115
             ::|:     ||| | : |  |   | :| :    | :: ||:| | | | ||      :
Db      63 VEESKINIGERSIFCIIEK-AEPERWNKLLRVKKPPHYVKVDWDKWVD-EDDEGSAGAAD 120

Qy     116 MELAHVE 122
           |::| :|
Db     121 MDMAGME 127
```

RESULT 13
AAG47700
ID AAG47700 standard; Protein; 258 AA.
XX
AC AAG47700;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 60150.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.

XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.

```
PR   16-SEP-1999;   99US-0154039.
PR   20-SEP-1999;   99US-0154779.
PR   22-SEP-1999;   99US-0155139.
PR   23-SEP-1999;   99US-0155486.
PR   24-SEP-1999;   99US-0155659.
PR   28-SEP-1999;   99US-0156458.
PR   29-SEP-1999;   99US-0156596.
PR   04-OCT-1999;   99US-0157117.
PR   05-OCT-1999;   99US-0157753.
PR   06-OCT-1999;   99US-0157865.
PR   07-OCT-1999;   99US-0158029.
PR   08-OCT-1999;   99US-0158232.
PR   12-OCT-1999;   99US-0158369.
PR   13-OCT-1999;   99US-0159293.
PR   13-OCT-1999;   99US-0159294.
PR   13-OCT-1999;   99US-0159295.
PR   14-OCT-1999;   99US-0159329.
PR   14-OCT-1999;   99US-0159330.
PR   14-OCT-1999;   99US-0159331.
PR   14-OCT-1999;   99US-0159637.
PR   14-OCT-1999;   99US-0159638.
PR   18-OCT-1999;   99US-0159584.
PR   21-OCT-1999;   99US-0160741.
PR   21-OCT-1999;   99US-0160767.
PR   21-OCT-1999;   99US-0160768.
PR   21-OCT-1999;   99US-0160770.
PR   21-OCT-1999;   99US-0160814.
PR   21-OCT-1999;   99US-0160815.
PR   22-OCT-1999;   99US-0160980.
PR   22-OCT-1999;   99US-0160981.
PR   22-OCT-1999;   99US-0160989.
PR   25-OCT-1999;   99US-0161404.
PR   25-OCT-1999;   99US-0161405.
PR   25-OCT-1999;   99US-0161406.
PR   26-OCT-1999;   99US-0161359.
PR   26-OCT-1999;   99US-0161360.
PR   26-OCT-1999;   99US-0161361.
PR   28-OCT-1999;   99US-0161920.
PR   28-OCT-1999;   99US-0161992.
PR   28-OCT-1999;   99US-0161993.
PR   29-OCT-1999;   99US-0162142.

  Query Match             14.3%;  Score 121;  DB 21;  Length 258;
  Best Local Similarity   27.6%;  Pred. No. 0.00011;
  Matches   35;  Conservative   25;  Mismatches   57;  Indels   10;  Gaps    5;

Qy       4 QHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIV-FSCKNADGVELYN-EIEFYAKVN 61
           :|    | :    :|:   : |: |  | ::   :  || |      :|  ::|   |||
Db       3 RHPEVKWAETTEKIFLTVVLADTKDTKVNLDPEGVFDFSAKVGPENHVYELKLELADKVN 62

Qy      62 SKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDE------E 115
             ::|:     ||| | : |  |   | :| :    | :: ||:| | | | ||      :
Db      63 VEESKINIGERSIFCIIEK-AEPERWNKLLRVKKPPHYVKVDWDKWVD-EDDEGSAGAAD 120

Qy     116 MELAHVE 122
           |::| :|
Db     121 MDMAGME 127


RESULT 14
AAG32123
ID   AAG32123 standard; Protein; 262 AA.
XX
AC   AAG32123;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID NO: 38695.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
XX
OS   Arabidopsis thaliana.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-0301439.
XX
PR   25-FEB-1999;   99US-0121825.
PR   05-MAR-1999;   99US-0123180.
PR   09-MAR-1999;   99US-0123548.
PR   23-MAR-1999;   99US-0125788.
PR   25-MAR-1999;   99US-0126264.
PR   29-MAR-1999;   99US-0126785.
PR   01-APR-1999;   99US-0127462.
PR   06-APR-1999;   99US-0128234.
PR   08-APR-1999;   99US-0128714.
PR   16-APR-1999;   99US-0129845.
PR   19-APR-1999;   99US-0130077.
PR   21-APR-1999;   99US-0130449.
PR   23-APR-1999;   99US-0130510.
PR   23-APR-1999;   99US-0130891.
PR   28-APR-1999;   99US-0131449.
PR   30-APR-1999;   99US-0132048.
PR   30-APR-1999;   99US-0132407.
PR   04-MAY-1999;   99US-0132484.
PR   05-MAY-1999;   99US-0132485.
PR   06-MAY-1999;   99US-0132486.
PR   06-MAY-1999;   99US-0132487.
PR   07-MAY-1999;   99US-0132863.
PR   11-MAY-1999;   99US-0134256.
PR   14-MAY-1999;   99US-0134218.
PR   14-MAY-1999;   99US-0134219.
PR   14-MAY-1999;   99US-0134221.
PR   14-MAY-1999;   99US-0134370.
PR   18-MAY-1999;   99US-0134768.
PR   19-MAY-1999;   99US-0134941.
PR   20-MAY-1999;   99US-0135124.
PR   21-MAY-1999;   99US-0135353.
PR   24-MAY-1999;   99US-0135629.
PR   25-MAY-1999;   99US-0136021.
PR   27-MAY-1999;   99US-0136392.
PR   28-MAY-1999;   99US-0136782.
PR   01-JUN-1999;   99US-0137222.
PR   03-JUN-1999;   99US-0137528.
PR   04-JUN-1999;   99US-0137502.
PR   07-JUN-1999;   99US-0137724.
PR   08-JUN-1999;   99US-0138094.
PR   10-JUN-1999;   99US-0138540.
PR   10-JUN-1999;   99US-0138847.
PR   14-JUN-1999;   99US-0139119.
PR   16-JUN-1999;   99US-0139452.
PR   16-JUN-1999;   99US-0139453.
PR   17-JUN-1999;   99US-0139492.
PR   18-JUN-1999;   99US-0139454.
PR   18-JUN-1999;   99US-0139455.
PR   18-JUN-1999;   99US-0139456.
PR   18-JUN-1999;   99US-0139457.
PR   18-JUN-1999;   99US-0139458.
PR   18-JUN-1999;   99US-0139459.
PR   18-JUN-1999;   99US-0139460.
PR   18-JUN-1999;   99US-0139461.
PR   18-JUN-1999;   99US-0139462.
PR   18-JUN-1999;   99US-0139463.
PR   18-JUN-1999;   99US-0139750.
PR   18-JUN-1999;   99US-0139763.
PR   21-JUN-1999;   99US-0139817.
PR   22-JUN-1999;   99US-0139899.
PR   23-JUN-1999;   99US-0140353.
PR   23-JUN-1999;   99US-0140354.
PR   24-JUN-1999;   99US-0140695.
PR   28-JUN-1999;   99US-0140823.
PR   29-JUN-1999;   99US-0140991.
```

PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 14.3%; Score 121; DB 21; Length 262;
Best Local Similarity 27.6%; Pred. No. 0.00011;
Matches 35; Conservative 25; Mismatches 57; Indels 10; Gaps 5;

```
Qy       4 QHARTLWYDRPMYVFMEFCVEDSTDVHVLIEDHRIV-FSCKNADGVELYN-EIEFYAKVN 61
           :|    | :    :|:   : |: |  | ::   :  || |      :|  ::|   |||
Db       7 RHPEVKWAETTEKIFLTVVLADTKDTKVNLDPEGVFDFSAKVGPENHVYELKLELADKVN 66

Qy      62 SKDSQDKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDE------E 115
             ::|:     ||| | : |  |   | :| :    | :: ||:| | | | ||      :
Db      67 VEESKINIGERSIFCIIEK-AEPERWNKLLRVKKPPHYVKVDWDKWVD-EDDEGSAGAAD 124

Qy     116 MELAHVE 122
           |::| :|
Db     125 MDMAGME 131
```

RESULT 15
AAM93819
ID AAM93819 standard; Protein; 362 AA.
XX
AC AAM93819;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide, SEQ ID NO: 3873.
XX
KW Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS Homo sapiens.

XX
PN EP1130094-A2.
XX
PD 05-SEP-2001.
XX
PF 07-JUL-2000; 2000EP-0114089.
XX
PR 08-JUL-1999; 99JP-0194486.
PR 11-JAN-2000; 2000JP-0118774.
PR 02-MAY-2000; 2000JP-0183765.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR WPI; 2001-524255/58.
DR N-PSDB; AAK94775.
XX
PT 830 Primers useful for synthesizing full length cDNA clones and their
PT use in genetic manipulation -
XX
PS Claim 8; SEQ ID NO 3873; 1380pp + sequence listing; English.
XX
CC The invention relates to primers for synthesising full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been
CC isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC molecules have been determined. Primers for synthesising the full length
CC cDNA are useful for clarifying the function of the protein encoded by
CC the cDNA. The full length clones were obtained by construction of full
CC length enriched cDNA libraries that were synthesised by the oligo-capping
CC method. The primers enable the production of the full length cDNA easily
CC without any special methods. The present sequence is a polypeptide
CC encoded by a full length human cDNA of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in CD-ROM format directly from EPO.
XX
SQ Sequence 362 AA;

Query Match 13.5%; Score 115; DB 22; Length 362;
Best Local Similarity 30.4%; Pred. No. 0.00076;
Matches 38; Conservative 23; Mismatches 56; Indels 8; Gaps 6;

```
Qy      10 WYDRPMYVFMEFCVEDSTDVHVLIEDHRIVFSCK--NADGVELYN-EIEFYAKVNSKDSQ 66
           |  |   :::   : |  :  : | :: : |  :   | |  :|   :||   |  :
Db      12 WAQRHRELYLRVELSDVQNPAISITENVLHFKAQGHGAKGDNVYEFHLEFLDLVKPEPVY 71

Qy      67 DKRSSRSITCFVRKWKEKVAWPRLTKEDIKPVWLSVDFDNWRDWEGDEEMELAHVEHYAE 126
            | : | :   |:| |    | ||||:: :|::|: ||| | | | | ||||   |   |
Db      72 -KLTQRQVNITVQK-KVSQWWERLTKQEKRPLFLAPDFDRWLD-ESDAEMELRAKEE--E 126

Qy     127 LLKKV 131
           | |:
Db     127 RLNKL 131
```

Search completed: March 20, 2003, 05:17:53
Job time : 69 secs